Cn-07 * predictors of acute severe lymphopenia during radiotherapy and temozolomide for high-grade glioma
CONCLUSIONS: Female gender, elder age, increased V25Gy of brain, and low pretreatment lymphocyte count are significant predictors of ASL during treatment of HGG. Maintaining V25Gy of brain below 66% may reduce the rate of ASL. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Huang, J., Robinson, C., DeWees, T., Campian, J., Mullen, D., Fergus, S., Kim, A., Dunn, G., Tran, D., Simpson, J. Tags: COMPLICATIONS OF THERAPY AND NEUROTOXICITY Source Type: research
At-26 * clinical management and outcome of histologically verified adult brainstem gliomas in switzerland: a retrospective analysis of 21 patients
CONCLUSIONS: Histologically verification of adult brainstem glioma is feasible and has an impact on postoperative treatment. Low-grade gliomas can simple be followed or treated with radiotherapy alone. Radiochemotherapy with temozolomide can safely be prescribed for high-grade gliomas without additional CNS toxicities. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Hundsberger, T., Tonder, M., Hottinger, A., Brugge, D., Roelcke, U., Putora, M., Stupp, R., Weller, M. Tags: ADULT CLINICAL TRIALS Source Type: research
At-15 * a phase ii study of antineoplastons a10 and as2-1 in patients with brainstem gliomas final report (protocol bt-11)
CONCLUSION: The results suggest that ANP shows efficacy and acceptable tolerability profile in patients with BSG, RPDIPG, and NDIPG. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Burzynski, S., Janicki, T., Marszalek, A., Burzynski, G. Tags: ADULT CLINICAL TRIALS Source Type: research
Convection enhanced delivery of carmustine to the murine brainstem: A feasibility study
Conclusion CED in the murine brainstem can be performed safely, is well tolerated and can be used to study efficacy of chemotherapeutic agents orthotopically. These results set the foundation for more CED studies in murine DIPG models. (Source: Journal of Neuroscience Methods)
Source: Journal of Neuroscience Methods - November 3, 2014 Category: Neuroscience Source Type: research
Nt-17 * treatment of diffuse intrinsic pontine glioma (dipg) with an oncolytic measles virus in combination with inhibitors of the pi3-kinase pathway
CONCLUSION: Measles virus has therapeutic potential in the treatment of DIPG tumors and the efficacy may be improved by simultaneously targeting the Akt-mTOR pathway. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Lal, S., Lawrence, S., Raffel, C. Tags: NOVEL THERAPEUTICS (CLINICAL AND/OR LABORATORY RESEARCH) Source Type: research
Et-64 * pre-clinical assessment of dissociative steroids as dexamethasone substitute for treatment in diffuse intrinsic pontine glioma (dipg)
CONCLUSIONS: VPB15 has similar or better efficacy vs. dexamethasone (DEX) in reducing pro-inflammatory signals in brainstem glioma cells in vitro, and VBP15-treated DIPG mice show better survival compared to dexamethasone in vivo. These pilot results warrant more extensive pre-clinical testing and possibly development of a clinical trial. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Wells, E., Khambampati, M., Yadavilli, S., Damsker, J., Hoffman, E., Packer, R., Nazarian, J. Tags: EXPERIMENTAL AND BIOLOGICAL THERAPEUTICS (CLINICAL AND/OR LABORATORY) Source Type: research
Ge-24 * characterizing intratumor heterogeneity and tumor extension in pediatric diffuse intrinsic pontine glioma
CONCLUSIONS: Significant intratumor heterogeneity may affect the accuracy of targeted diagnosis in small biopsy specimens. A better understanding of these differences will help in improving therapy and devising accurate molecular-based tumor grading. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Panditharatna, E., Kambhampati, M., Ho, C.-Y., Gordish-Dressman, H., Siu, A., Hwang, E., Stampar, M., Packer, R., Nazarian, J. Tags: GENOMICS AND MOLECULAR PATHOLOGY (CLINICAL AND/OR LABORATORY RESEARCH) Source Type: research
Ni-44 * liposomal nanoparticles for targeting and imaging of pediatric brain tumors
This study reports the targeting and real-time optical imaging of brainstem tumors using liposomal nanocarriers. Patients with infiltrating brainstem gliomas (BSG) known as diffuse intrinsic pontine gliomas (DIPGs) have one of the poorest survival rates. Blood brain barrier (BBB) is the main obstacle in the delivery of drugs and contrast agents to DIPGs. OBJECTIVE: Here, we demonstrate the specific delivery of liposomal nanoparticles containing Evans blue (nano-EB) to tumor in a murine model of BSG. METHODS/DESIGN: Mice with brainstem tumors were tail vein injected with nano-EB and in vivo tumor enhancement was monitored b...
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Kambhampati, M., Yadavilli, S., McNeeley, K. M., Pai, S. B., Yu, Q., Bellamkonda, R., Fernandes, R., Packer, R. J., Nazarian, J. Tags: NEURO-IMAGING (CLINICAL AND/OR LABORATORY RESEARCH) Source Type: research
PM-12 * Pax3 EXPRESSION ENHANCES PDGF-B-INDUCED BRAINSTEM GLIOMAGENESIS AND CHARACTERIZES A SUBSET OF BRAINSTEM GLIOMA
High-grade Brainstem glioma (BSG), also known as Diffuse Intrinsic Pontine Glioma (DIPG), is an incurable pediatric brain cancer. Increasing evidence supports the existence of regional differences in gliomagenesis such that BSG is thought to be a distinct disease from glioma of the cerebral cortex (CG). In an effort to elucidate unique characteristics of BSG, we conducted expression analysis of mouse PDGF-B-driven BSG and CG initiated in Nestin progenitor cells and identified a short list of expression changes specific to the brainstem gliomagenesis process, including upregulation of paired box 3 (Pax3). In the neonatal mo...
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Misuraca, K., Diaz, A., Baker, S., Becher, O. Tags: PRECLINICAL TUMOR/ANIMAL MODELS Source Type: research
Pt-02 * long-term survival (>20 years) of a child with brainstem glioma treated with antineoplastons a10 and as2-1: a case report
This report discusses a case of a 12-year-old male diagnosed with tectal glioma that had the onset of symptoms in November 1993. Initial treatment consisted of the placement of a ventriculoperitoneal shunt. After six years of stabilization of the disease, there had been an increase in the tumor size with signs of malignant transformation. In August 2001, he started treatment with Antineoplaston (ANP) A10 and AS2-1 infusions and continued for 20 months according to Phase II Protocol BT-09. The dosage of A10 was maintained between 12.5 and 14.7 g/kg/d and AS2-1 from 0.3 and 0.4 g/kg/d. He obtained a complete response and was...
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Burzynski, G., Janicki, T., Marszalek, A., Burzynski, S. Tags: PEDIATRIC CLINICAL TRIALS Source Type: research
Rt-08 * proton therapy (pt) large-volume re-irradiation for recurrent glioma: overall survival (os) and toxicity outcomes
CONCLUSION: Large-volume PT re-irradiation for recurrent glioma is safe and associated with promising OS outcomes, particularly in the setting of bevacizumab-refractory tumors. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Desai, B., Rockne, R., Rademaker, A., Raizer, J., Paleologos, N., Merrell, R., Grimm, S., Azeem, S., Hartsell, W., Sweeney, P., Swanson, K., Gondi, V. Tags: RADIATION THERAPY (CLINICAL AND/OR LABORATORY RESEARCH) Source Type: research
Rt-32 * clinical profile and outcomes in brainstem glioma. an institutional experience
CONCLUSIONS: Brain stem glioma in pediatric age group is associated with worse outcomes than in adults. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Syed, F., Lachi, P., Keshava, R., Syed, A., Nair, D., Krishna, V., Joseph, D., Irrakula, M., Pamidighantam, S., Naidu, K. Tags: RADIATION THERAPY (CLINICAL AND/OR LABORATORY RESEARCH) Source Type: research
Sc-37 * the role of ng2 expressing progenitor cells in diffuse intrinsic pontine glioma
We examined NG2 expression in frozen brainstem specimens of DIPGs and observed significant NG2 expression in DIPGs [10 of 14 (71 %), fold change = 33, p < 0.05)] as compared to the adjacent normal tissue. NG2 expression was associated with histone 3 K27M mutation [8 of 10 (80 %)]. Two mechanisms of NG2 regulation in DIPG were identified: i) histone 3 binds to NG2 promoter, and ii) miR 129-2 negatively regulates NG2. We detected downregulation of miR129-2 in 85.7% (6 of 7) of DIPG tumors compared to normal tissue (FC = -30.79, n = 7 pairs). We also found overall hypermethylation at 8 CpG loci corresponding to the miR129-...
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Yadavilli, S., Becher, O. J., Kambhampati, M., Packer, R. J., Nazarian, J. Tags: STEM CELLS Source Type: research
Histologically Proven Radiation‐Induced Brainstem Glioma 93 Months After External Beam Radiotherapy for Pituitary Macroadenoma: Radiation Treatment Dose and Volume Correlation
ABSTRACT
Patient is a 29‐year‐old with a history of recurrent growth hormone‐secreting pituitary macroadenoma diagnosed 12 years prior to presentation. Eight years prior to current presentation, the patient underwent re‐resection and received 50.4 Gy external beam radiotherapy (EBRT) in 28 fractions of 1.8 Gy each. Serial postradiation MRIs demonstrated regression in pituitary tumor size. Patient presented with new headaches 7.5 years after completing EBRT. Brain MRI demonstrated new FLAIR hyperintensity and contrast enhancement within the pons and medulla, corresponding to the 36 Gy isodose line of each radiation ...
Source: Journal of Neuroimaging - October 28, 2014 Category: Radiology Authors: Salim E. Abboud, Leo J. Wolansky, Sunil V. Manjila, Simon S. Lo, Baha M. Arafah, Warren R. Selman, Marta E. Couce, Lisa R. Rogers Tags: Case Report Source Type: research
Diagnostic challenges, management and outcomes of midline low-grade gliomas
Conclusions
Diagnosis of midline LGGs is complicated by both limitations of biopsy and imaging. Midline tumours have a poorer prognosis compared to lobar equivalents and survival differences are probably due to the absence of significant surgical intervention in midline locations. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 23, 2014 Category: Cancer & Oncology Source Type: research
